Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 10/20 | 0.51 |
| ▸ | KIT | P10721 | 11/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29568648 | 1.00 | FLT3 (0.51) | FLT3KITHDAC6FGFR1KDR | |
| SCHEMBL24244915 | 1.00 | FLT3 (0.51) | FLT3KITHDAC6FGFR1KDR | |
| SCHEMBL22551215 | 1.00 | FLT3 (0.51) | FLT3KITHDAC6FGFR1KDR | |
| SCHEMBL31561380 | 1.00 | FLT3 (0.51) | FLT3KITHDAC6FGFR1KDR | |
| SCHEMBL22551178 | 0.88 | FLT3 (0.56) | FLT3KITHDAC6FGFR1 | |
| SCHEMBL29568400 | 0.88 | FLT3 (0.56) | FLT3KITHDAC6FGFR1 | |
| SCHEMBL22551226 | 0.88 | KIT (0.44) | FLT3KITHDAC6KDR | |
| SCHEMBL22551235 | 0.88 | KIT (0.44) | FLT3KITHDAC6KDR | |
| SCHEMBL22551208 | 0.84 | FLT3 (0.56) | FLT3KITHDAC6FGFR1FGFR2 | |
| SCHEMBL22551185 | 0.84 | FLT3 (0.56) | FLT3KITHDAC6FGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3956315-B1 | BENZO- AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS | Rottapharm Biotech Srl (IT) | 2025-04-16 | — | — | EP | claimed |
| US-20220041559-A1 | BENZO-AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2022-02-10 | — | — | US | claimed |
| CN-114008026-A | Benzopyrazoles and pyridopyrazoles as protein kinase inhibitors | 罗达制药生物技术有限责任公司 | 2022-02-01 | — | — | CN | claimed |
| EP-3725777-A1 | BENZO- AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS | Rottapharm Biotech S.r.l. (IT) | 2020-10-21 | — | — | EP | claimed |
| EP-3956315-B1 | BENZO- AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS | Rottapharm Biotech Srl (IT) | 2025-04-16 | — | — | EP | disclosed |
| US-20220041559-A1 | BENZO-AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2022-02-10 | — | — | US | disclosed |
| CN-114008026-A | Benzopyrazoles and pyridopyrazoles as protein kinase inhibitors | 罗达制药生物技术有限责任公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-3725777-A1 | BENZO- AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS | Rottapharm Biotech S.r.l. (IT) | 2020-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041559-A1 | BENZO-AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS | PDXK, MAP4K2, PLK2 | FLT3 315/4885KIT 1734/4885HDAC6 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.